We are live on
!
Find out more
SSC
Spruce Street Capital Portfolio holdings
AUM
$510M
This Fund
S&P 500
This Quarter
Est. Return
+66.43%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$303M
AUM Growth
–
Cap. Flow
+$250M
Cap. Flow
% of AUM
82.69%
Top 10 Holdings %
Top 10 Hldgs %
70.8%
Holding
27
New
27
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CDTX
Cidara Therapeutics
CDTX
|
+$37.5M |
| 2 |
Relay Therapeutics
RLAY
|
+$21.3M |
| 3 |
Vaxcyte
PCVX
|
+$17.9M |
| 4 |
LBRX
LB Pharmaceuticals
LBRX
|
+$17.6M |
| 5 |
Kiniksa Pharmaceuticals
KNSA
|
+$17.4M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CDTX
1
DELISTED
Cidara Therapeutics
CDTX
| $51.3M | 16.95% |
+232,269
| New | +$37.5M |
|
|
2
Relay Therapeutics
RLAY
$4.33B
| $25.2M | 8.34% |
+2,984,125
| New | +$21.3M |
|
|
LBRX
3
LB Pharmaceuticals
LBRX
$1.56B
| $22.4M | 7.4% |
+1,005,593
| New | +$17.6M |
|
4
Relmada Therapeutics
RLMD
$489M
| $19.7M | 6.52% |
+4,086,181
| New | +$13.7M |
|
|
5
Vaxcyte
PCVX
$9.21B
| $18.5M | 6.1% |
+400,360
| New | +$17.9M |
|
|
6
Kiniksa Pharmaceuticals
KNSA
$6.19B
| $17.9M | 5.93% |
+434,982
| New | +$17.4M |
|
7
EyePoint Inc
EYPT
$420M
| $17.9M | 5.93% |
+981,543
| New | +$13.9M |
|
8
Savara
SVRA
$1.14B
| $14.5M | 4.8% |
+2,411,093
| New | +$11.8M |
|
9
Erasca
ERAS
$6.16B
| $14.5M | 4.78% |
+3,889,632
| New | +$10.9M |
|
10
Dianthus Therapeutics
DNTH
$6.16B
| $12.3M | 4.05% |
+297,437
| New | +$11.5M |
|
11
Surrozen
SRZN
$282M
| $9.76M | 3.23% |
+432,040
| New | +$6.99M |
|
12
Ocular Therapeutix
OCUL
$2.37B
| $9.52M | 3.14% |
+783,999
| New | +$9.52M |
|
13
SAB Biotherapeutics
SABS
$329M
| $8.22M | 2.72% |
+2,198,502
| New | +$7.23M |
|
14
Inhibikase Therapeutics
IKT
$349M
| $7.34M | 2.43% |
+3,581,603
| New | +$5.7M |
|
15
Enliven Therapeutics
ELVN
$4.48B
| $6.87M | 2.27% |
+446,084
| New | +$8.89M |
|
16
Minerva Neurosciences
NERV
$230M
| $6.66M | 2.2% |
+1,655,500
| New | +$6.15M |
|
|
ABVX
17
Abivax
ABVX
$10.1B
| $6.62M | 2.19% |
+49,119
| New | +$5.36M |
|
|
HELP
18
Cybin Inc
HELP
$951M
| $6.3M | 2.08% |
+770,000
| New | +$4.96M |
|
|
KALV
19
DELISTED
KalVista Pharmaceuticals
KALV
| $6.27M | 2.07% |
+387,968
| New | +$5.14M |
|
20
Enanta Pharmaceuticals
ENTA
$411M
| $6.15M | 2.03% |
+389,687
| New | +$4.95M |
|
21
Alto Neuroscience
ANRO
$1.42B
| $3.97M | 1.31% |
+222,844
| New | +$2.81M |
|
|
LONA
22
LeonaBio Inc
LONA
$72.8M
| $2.98M | 0.98% |
+393,701
| New | +$1.8M |
|
|
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
| $1.95M | 0.64% |
+77,997
| New | +$1.98M |
|
24
Alector
ALEC
$257M
| $1.74M | 0.58% |
+1,117,986
| New | +$1.98M |
|
25
Lexeo Therapeutics
LXEO
$404M
| $1.74M | 0.57% |
+175,000
| New | +$1.6M |
|
Similar funds
TCM
CRWM
AG
TGY2IT
AWM
RPSA
WCP
MPPLM
Spruce Street Capital's Q4 2025 Portfolio in Review
Q4 2025 is the first quarter with a 13F filing on record for Spruce Street Capital, which disclosed 27 positions worth $303M. Its ten largest holdings account for 71% of the portfolio.
Its largest position is Cidara Therapeutics: 232,269 shares worth $51.3M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Spruce Street Capital's largest Q4 2025 buy was Cidara Therapeutics: 232,269 shares worth $51.3M.
- Spruce Street Capital's ten largest holdings make up 71% of its $303M portfolio in Q4 2025.
- Spruce Street Capital disclosed 27 positions in Q4 2025, its first 13F filing on record.
Based on Spruce Street Capital's 13F filing for Q4 2025, filed 13 Feb 2026.